Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ESMO Congress 2026 · Barcelona, Spain
11 shown of 2,484 total abstracts
  1. Abstract 69722026-09-04 · 20:00 CT · Hall B1
    Real-world effectiveness of Opdivo vs standard of care in RCC
    E. Winer, R. Herbst, M. Reck, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  2. Abstract 65572026-09-05 · 20:30 CT · S100A
    KEYNOTE-153: Keytruda (pembrolizumab) 2L in RCC
    S. Peters, T. Mok, H. Borghaei · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  3. Abstract 60222026-09-02 · 13:45 CT · E450
    Quality of life outcomes with Opdivo in patients with RCC
    F. Andre, H. Rugo · Mayo Clinic
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  4. Abstract 65812026-09-05 · 18:30 CT · S100A
    Long-term follow-up of Opdivo 2L for RCC: CheckMate-627
    E. Winer, C. Saura, P. Schmid · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  5. Abstract 69542026-09-04 · 21:00 CT · Arie Crown Theater
    Quality of life outcomes with Keytruda in patients with RCC
    T. Mok, C. Saura, R. Herbst, et al. · Institut Gustave Roussy
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  6. Abstract 63522026-09-03 · 20:00 CT · S100A
    Long-term follow-up of Opdivo neoadjuvant for RCC: CheckMate-545
    S. Antonia, C. Robert, J. Cortes, et al. · Massachusetts General Hospital
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  7. Abstract 63552026-09-05 · 21:15 CT · Hall B1
    KEYNOTE-187: Keytruda (pembrolizumab) neoadjuvant in RCC
    R. Herbst, P. Schmid, M.C. Garassino · National Cancer Center Japan
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  8. Abstract 66452026-09-03 · 16:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-866 study)
    L. Paz-Ares, H. Rugo, G. Curigliano, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  9. Abstract 63022026-09-05 · 13:45 CT · S406
    Real-world effectiveness of Keytruda vs standard of care in RCC
    G. Curigliano, C. Saura, M.C. Garassino · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  10. Abstract 60312026-09-01 · 21:00 CT · S406
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-556 study)
    L. Paz-Ares, F. Andre · Institut Gustave Roussy
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  11. Abstract 65082026-09-03 · 21:30 CT · E450
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-881
    J. Cortes, S. Modi, S. Tolaney, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.